

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
36822	13/NW/0208	121193	NCRN568 - ARROVEN - brentuximab vedotin PASS	Number Agreed	18	18	Date Agreed	26/06/2018	14	26/06/2018	14	Recruitment Finished	Participants sought, 14 identified within time frame.
36823	15/NE/0167	171524	MLN9708 in Multiple Myeloma Not Treated with Stem Cell transplantation - MILLENIUM	Number Agreed	4	4	Date Agreed	01/07/2017	4	19/10/2018	4	Recruitment Finished	
36824	15/SW/0248	186033	VX14-661-110 Cystic Fibrosis	Number Agreed	3	3	Date Agreed	16/07/2018	14	30/06/2018	14	Recruitment Finished	
36825	15/LO/2045	193136	CHIL 5229 SMT C1100 in Ambulatory Boys with DMD	Number Agreed	2	2	Date Agreed	02/03/2017	5	27/06/2018	5	Recruitment Finished	
36826	15/EM/0521	184930	CANC - 5309	Number Agreed	4	4	Date Agreed	31/07/2018	5	22/06/2018	5	Recruitment Finished	
36827	16/EM/0167	179908	RESP 4602	Number Agreed	3	3	Date Agreed	31/01/2019	1	16/07/2018	1	Recruitment Finished	Sponsor closed recruitment early.
36828	16/WM/0395	210507	RENA 4591 (ASCEND-D)	Number Agreed	4	4	Date Agreed	26/04/2018	2	07/06/2018	2	Recruitment Finished	Participants sought, 2 identified within time frame.
36829	15/WS/0170	184797	HAEM 4528	Number Agreed	4	4	Date Agreed	19/01/2019	7	07/09/2018	7	Recruitment Finished	
36830	15/EM/0500	188865	RESP 4446	Number Agreed	2	2	Date Agreed	20/09/2017	0	20/09/2018	0	Recruitment Finished	Participants sought, none identified within time frame.
36831	16/WM/0507	218607	EXCEED	Number Agreed	4	4	Date Agreed	01/06/2018	2	23/08/2018	2	Recruitment Finished	Participants sought, 2 identified within time frame.
36832	17/LO/0441	222471	MK-3475-604 (Phase 3 trial of etoposide/platinum with or without pembrolizumab)	Number Agreed	4	4	Date Agreed	30/09/2021	1	09/07/2018	1	Recruitment Finished	Sponsor closed recruitment early.
36833	17/WA/0183	225334	M16-043 Phase 3 patients with treatment naive AML	Number Agreed	2	2	Date Agreed	22/08/2019	3	19/04/2018	3	Recruitment Finished	
36834	17/NE/0151	223815	SGI-110 vs Treatment Choice in Adults with Previously Treated AML	Number Agreed	2	2	Date Agreed	29/09/2018	3	17/09/2018	3	Recruitment Finished	
36835	16/SC/0035	194232	A Phase III Study of Pembrolizumab vs. Chemotherapy in MSI-H or dMMR S	Number Agreed	3	3	Date Agreed	30/04/2018	1	30/04/2018	1	Recruitment Finished	Participants sought, 1 identified within time frame.
36836	17/NS/0098	233221	SAGE-Observational study of glycaemic control & QoL in Type 1 diabetes	Number Agreed	20	20	Date Agreed	30/04/2018	21	03/05/2018	21	Recruitment Finished	
36837	17/NW/0584	233211	Study of Serlopitant for the Treatment of Refractory Chronic Cough	Number Agreed	5	5	Date Agreed	30/04/2018	1	30/04/2018	1	Recruitment Finished	Participants sought, 1 identified within time frame.
36838	17/EM/0425	236800	Retrospective review of current treatment pathways for MF in the UK	Number Agreed	15	15	Date Agreed	31/01/2018	19	30/04/2018	19	Recruitment Finished	
36839	16/LO/1709	212830	Semaglutide in NASH	Number Agreed	2	2	Date Agreed	19/11/2018	0	12/07/2018	0	Recruitment Finished	Sponsor closed recruitment early.
36840	18/SC/0098	241440	Subcut Daratumumab in combination with standard treatment regimens	Number Agreed	3	3	Date Agreed	27/10/2020	5	19/07/2018	5	Recruitment Finished	
36841	18/NE/0200	244356	VX17-445-102 Efficacy and Safety of VX-445/TEZ/IVA in CF Het-min	Number Agreed	3	3	Date Agreed	30/06/2019	2	22/08/2018	2	Recruitment Finished	Sponsor closed recruitment early.
36842	18/NE/0201	244419	VX17-445-103 Efficacy and Safety of VX-445/TEZ/IVA in CF Homozygous	Number Agreed	3	3	Date Agreed	31/01/2019	2	02/11/2018	2	Recruitment Finished	Sponsor closed recruitment early.
36843	17/NW/0656	235797	ODYSSEY LEGACY.	Number Agreed	21	21	Date Agreed	31/12/2018	16	05/09/2018	16	Withdrawn By Sponsor	Sponsor faced challenges with trial, and so withdrew the trial internationally.
36844	18/LO/1002	242654	Study of GSK2857196 in pts. with RRMM who have failed on Daratumumab	Number Agreed	2	2	Date Agreed	07/12/2018	1	19/10/2018	1	Recruitment Finished	Sponsor closed recruitment early.
36845	18/HRA/1748	243170	Venetoclax (ABT-199)	Number Agreed	3	3	Date Agreed	06/08/2018	3	06/08/2018	3	Recruitment Finished	
36848	17/EM/0060	215678	Protocol I1F-MC-RHBY	Number Agreed	1	1	Date Agreed	01/01/2019	1	01/01/2019	1	Recruitment Finished	
36849	17/EE/0204	207238	BCX7353 as a treatment for acute HAE attacks	Number Agreed	3	3	Date Agreed	01/09/2018	4	17/10/2018	4	Recruitment Finished	
36850	18/NW/0507	250276	VX-121	Number Agreed	1	1	Date Agreed	13/02/2019	2	13/02/2019	2	Recruitment Finished	
36903	13/ES/0005	114717	NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC) / AZA-MDS-003	Number Agreed	3	3	Date Agreed	31/07/2020	1	27/07/2018	1	Recruitment Finished	Sponsor closed recruitment early.
36904	16/EM/0312	205489	Safety And Efficacy Of Orally Administered DS102 In NAFLD Patients	Number Agreed	5	5	Date Agreed	30/06/2018	4	27/07/2018	4	Recruitment Finished	Participants sought, 4 identified within time frame.
36905	17/EE/0074	217180	Pfizer B7461006 NSCLC	Number Agreed	2	2	Date Agreed	31/10/2018	1	31/10/2018	1	Recruitment Finished	Participants sought, 1 identified within time frame.
36906	16/EE/0071	193751	Unravel MGUS	Number Agreed	100	100	Date Agreed	01/02/2019	64	01/02/2019	64	Recruitment Finished	Participants sought, 64 identified within time frame.
36907	17/SW/0279	231649	MO39171 - Atezolizumab in locally advanced or metastatic NSCLC	Number Agreed	6	6	Date Agreed	30/04/2019	4	08/11/2018	4	Recruitment Finished	Sponsor closed recruitment early.
36908	18/YH/0069	242258	GLOW study	Number Agreed	2	2	Date Agreed	03/03/2019	1	16/01/2019	1	Recruitment Finished	Sponsor closed recruitment early.
36909	17/LO/1103	230709	Research doses of BAY1817080 in healthy males & PoC in chronic cough pts	Number Agreed	2	2	Date Agreed	31/01/2019	1	31/01/2019	1	Recruitment Finished	Participants sought, 1 identified within time frame, phase 1 study and patients required to come in weekly.
36910	18/EM/0228	248988	Anti-viral effect of PC786 on RSV infection in HSCT recipients	Number Agreed	3	3	Date Agreed	31/08/2019	0	08/03/2019	0	Recruitment Finished	Sponsor closed recruitment early.